Urology News and Research

Latest Urology News and Research

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.

20 Apr 2007

Long-term survival probability in men with clinically localized prostate cancer

Randomized studies comparing conservative therapy to definitive therapy in men with prostate cancer (CaP) are underway, but not yet available.

20 Apr 2007

Indevus Pharmaceuticals submits supplemental NDA for VALSTAR

Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.

20 Apr 2007

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

All physicians involved in the treatment of PBS/IC understand that the placebo effect likely plays a major role in treatment, and is important when evaluating drug trials.

19 Apr 2007

Factors that dictate risk of developing primary or secondary cancer

Every day, people make assumptions, educated and not, about their risk for developing cancer.

18 Apr 2007

Chemicals in cruciferous vegetables may provide cancer-fighting benefit

Chemicals in cruciferous vegetables, such as broccoli, watercress, cabbage and cauliflower, appear to not only stop human prostate cancer cells from growing in mice but also may cut off the formation of blood vessels that "feed" tumors, says a University of Pittsburgh Cancer Institute study.

18 Apr 2007

Aspirin may modestly reduce cancer risk

A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

18 Apr 2007

Indevus and Valera complete merger

Indevus Pharmaceuticals and Valera Pharmaceuticals have announced the completion of their previously announced merger, which became effective at 12:01 a.m., April 18, 2007.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Advanced age associated with poorer bladder cancer-specific survival in radical cystectomy patients

Traditional wisdom taught in urological residency has been that healthy octogenarians with bladder cancer may be offered radical cystectomy without a significantly increased incidence of postoperative complications.

18 Apr 2007

Predicting cancer risk in the long term

Every day, people make assumptions, educated and not, about their risk for developing cancer.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

Report on radical prostatectomy for octogenarians

There is no defined recommendation for when to stop prostate cancer (CaP) screening, except when the life expectancy decreases to less than 10 years.

16 Apr 2007

Functional diffusion map measures effectiveness of treatment for prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a new imaging technique that can measure the effectiveness of treatment for prostate cancer that has spread to the bones.

16 Apr 2007

Robotics in urology leads to decreased surgical and medical complications

Mani Menon, MD Detroit, Michigan, USA presented "The Role of Robotics in Urology" as the AUA Lecture at the plenary session of the EAU on Friday March 23, 2007.

15 Apr 2007

Lower educational level makes some men more vulnerable to the effects of prostate cancer

Among men who have received similar treatments for prostate cancer, those with less education , particularly those who did not graduate from high school , experience a significant drop in their quality of life after treatment compared with men who have more education, according to a study led by researchers at the San Francisco VA Medical Center (SFVAMC).

15 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007